Abstract
Receptor protein tyrosine phosphatases (RPTPs) are involved in many cellular processes, including the regulation of adhesion, migration and cellular signaling. Many RPTPs are putative tumor suppressors because of the transcriptional and translational changes observed in their expression during tumorigenesis. Recently, RPTPs were shown to be post-translationally regulated during tumorigenesis by proteolysis in a manner similar to proteolysis of the Notch receptor. There is accumulating evidence that proteolysis of RPTPs influence their cellular function and that RPTP fragments may function as oncogenes. By exploiting what is known about RPTP ligand binding domains and crystal structures of ligand-RPTP interfaces, we describe novel molecular diagnostics that have been or can be developed to identify tumor margins and target tumor tissues.
Keywords: Cell-cell interactions, cell-cell adhesion, receptor protein tyrosine phosphatase, RPTPs, cancer, Tumor-derived, Notch receptor, CAMs, Laminin/nidogen, ECD, ADAM
Anti-Cancer Agents in Medicinal Chemistry
Title: Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools
Volume: 11 Issue: 1
Author(s): Sonya E.L. Craig and Susann M. Brady-Kalnay
Affiliation:
Keywords: Cell-cell interactions, cell-cell adhesion, receptor protein tyrosine phosphatase, RPTPs, cancer, Tumor-derived, Notch receptor, CAMs, Laminin/nidogen, ECD, ADAM
Abstract: Receptor protein tyrosine phosphatases (RPTPs) are involved in many cellular processes, including the regulation of adhesion, migration and cellular signaling. Many RPTPs are putative tumor suppressors because of the transcriptional and translational changes observed in their expression during tumorigenesis. Recently, RPTPs were shown to be post-translationally regulated during tumorigenesis by proteolysis in a manner similar to proteolysis of the Notch receptor. There is accumulating evidence that proteolysis of RPTPs influence their cellular function and that RPTP fragments may function as oncogenes. By exploiting what is known about RPTP ligand binding domains and crystal structures of ligand-RPTP interfaces, we describe novel molecular diagnostics that have been or can be developed to identify tumor margins and target tumor tissues.
Export Options
About this article
Cite this article as:
E.L. Craig Sonya and M. Brady-Kalnay Susann, Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941244
DOI https://dx.doi.org/10.2174/187152011794941244 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Anti-breast Cancer Agents, Quinolines, Targeting Gap Junction
Medicinal Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Targeting Brain Cancer Cells by Nanorobot, a Promising Nanovehicle: New Challenges and Future Perspectives
CNS & Neurological Disorders - Drug Targets Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Editorial (Thematic Issue: Special Issue on Herbal Medicines and Nano-Drug Delivery Systems)
Current Signal Transduction Therapy In vivo Fluorescence Detection in Surgery: A Review of Principles, Methods, and Clinical Applications
Current Medical Imaging dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synergistic Combination of Doxorubicin and Paclitaxel Delivered by Blood Brain Barrier and Glioma Cells Dual Targeting Liposomes for Chemotherapy of Brain Glioma
Current Pharmaceutical Biotechnology Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design Recent Patents on the Development of c-Met Kinase Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Transmembrane Protein 166 and its Significance
Protein & Peptide Letters